Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Clinical Rheumatology
Published in: Clinical Rheumatology 8/2007

01-08-2007 | Review Article

Burden and control of musculoskeletal conditions in developing countries: a joint WHO/ILAR/BJD meeting report

Author: Bruce Pfleger

Published in: Clinical Rheumatology | Issue 8/2007

Login to get access

Excerpt

The World Health Organization (WHO) has worked extensively with the International League of Associations for Rheumatology (ILAR) and the Bone and Joint Decade 2000–2010 (BJD) towards means for prevention, diagnosis and management of musculoskeletal or rheumatic conditions. ILAR represents an umbrella organisation for regional and national rheumatic societies and has embarked upon epidemiological assessment of the prevalence of rheumatic conditions primarily in developing countries through the Community Oriented Program for Control of Rheumatic Diseases (COPCORD). In addition to documenting the extent of rheumatic conditions, the WHO-initiated COPCORD programme has provided education to patients and health professionals and treatment to those afflicted. The BJD serves as an umbrella organisation to dozens of National Networks and hundreds of organisations worldwide with a stake in musculoskeletal conditions. The WHO has worked closely with the scientific group of the BJD, the Bone and Joint Monitor project, to help document the burden of musculoskeletal conditions. …
Appendix
Available only for authorised users
Footnotes
1
SF-36 health survey, Medical Outcomes Trust, Waltham, MA, USA.
 
2
Instrument to describe and value health, EuroQol Group.
 
Literature
1.
Woolf AD (2003) The bone and joint decade. strategies to reduce the burden of disease: the bone and joint monitor project. J Rheumatol 30(Suppl 67):6–9
2.
Murray CJL, Lopez AD (eds) (1996) The global burden of disease: a comprehensive assessment of mortality and disability from diseases, injuries and risk factors in 1990 and projected to 2020. Harvard University Press, Cambridge, MA (Global Burden of Disease and Injury Series, Vol. 1)
3.
Murray CJL, Lopez AD (eds) (1996) Global health statistics: A compendium of incidence, prevalence and mortality estimates for over 200 conditions. Harvard University Press, Cambridge, MA (Global Burden of Disease and Injury Series, Vol. 2)
4.
The world health report 2000: Health systems: Improving performance. World Health Organisation, Geneva
5.
The world health report 2001: Mental health: New understanding, New hope. World Health Organisation, Geneva
6.
The world health report 2002: Reducing risks, Promoting healthy life. World Health Organization, Geneva
7.
The world health report 2003: Shaping the future. World Health Organization, Geneva
8.
The world health report 2004: Changing history. World Health Organization, Geneva
9.
The burden of musculoskeletal conditions at the start of the new millennium. Report of a WHO scientific group (2003). World Health Organization, Geneva (WHO Technical Report Series, No. 919)
10.
Ezzati M, Lopez AD, Rodgers A, Vander HS, Murray CJ (2002) Selected major risk factors and global and regional burden of disease. Lancet 360(9343):1347–1360PubMedCrossRef
11.
Kellgren JH (1962) Diagnostic criteria for population studies. Bull Rheum Dis 13:291–292PubMed
12.
Arnett FC, Edworthy SM, Bloch DA et al (1988) The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum 31(3):315–324PubMedCrossRef
13.
Wood PHN (1988) Nomenclature and classification of arthritis in children. EULAR Bulletin 4:101
14.
Brewer EJ Jr., Bass J, Baum J et al (1977) Current proposed revision of JRA Criteria. JRA criteria subcommittee of the diagnostic and therapeutic criteria committee of the American rheumatism section of the arthritis foundation. Arthritis Rheum 20(2 Suppl):195–199PubMed
15.
Kellgren JH, Lawrence JS (1958) Osteo-arthritis and disk degeneration in an urban population. Ann Rheum Dis 17(4):388–397PubMedCrossRef
16.
Wallace SL, Robinson H, Masi AT et al (1977) Preliminary criteria for the classification of the acute arthritis of primary gout. Arthritis Rheum 20:895–900PubMedCrossRef
17.
Metadata
Title
Burden and control of musculoskeletal conditions in developing countries: a joint WHO/ILAR/BJD meeting report
Author
Bruce Pfleger
Publication date
01-08-2007
Publisher
Springer-Verlag
Published in
Clinical Rheumatology / Issue 8/2007
Print ISSN: 0770-3198
Electronic ISSN: 1434-9949
DOI
https://doi.org/10.1007/s10067-007-0645-7

Other articles of this Issue 8/2007

Clinical Rheumatology 8/2007 Go to the issue

Original Article

Effects of hyaluronan on nitric oxide levels and superoxide dismutase activities in synovial fluid in knee osteoarthritis

Case Report

Treatment of refractory temporal arteritis with adalimumab

Case Report

Mononeuritis multiplex as a presenting feature of Wegener granulomatosis: a case report

Original Article

The relationship between nail- and distal phalangeal bone involvement severity in patients with psoriasis

Case Report

Central nervous system lymphoma in a patient with Sjogren’s syndrome and autoimmune thyroiditis (Hashimoto’s thyroiditis)

Original Article

Brazilian-Portuguese version of the Health Assessment Questionnaire for Spondyloarthropathies (HAQ-S) in patients with ankylosing spondylitis: a translation, cross-cultural adaptation, and validation
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

Watch now

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits